Platinum Concentration and Pathologic Response to Cisplatin-Based Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer

被引:6
|
作者
Guancial, Elizabeth A. [1 ]
Kilari, Deepak [2 ]
Xiao, Guang-Qian [3 ]
Abu-Farsakh, Sohaib H. [3 ]
Baran, Andrea [4 ]
Messing, Edward M. [5 ]
Kim, Eric S. [1 ]
机构
[1] Univ Rochester, Dept Med, James P Wilmot Canc Inst, Rochester, NY USA
[2] Med Coll Wisconsin, Dept Med, Milwaukee, WI 53226 USA
[3] Univ Rochester, Dept Pathol, Rochester, NY 14627 USA
[4] Univ Rochester, Dept Biostat & Computat Biol, Rochester, NY USA
[5] Univ Rochester, Dept Urol, Rochester, NY USA
来源
PLOS ONE | 2016年 / 11卷 / 05期
关键词
COPPER TRANSPORTER CTR1; UROTHELIAL CARCINOMA; EXPRESSION; METHOTREXATE; GEMCITABINE; VINBLASTINE; DOXORUBICIN; CYSTECTOMY; ERCC1;
D O I
10.1371/journal.pone.0155503
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background Platinum (Pt)-based chemotherapy is the standard of care for muscle-invasive bladder cancer (MIBC). However, resistance is a major limitation. Reduced intratumoral drug accumulation is an important mechanism of platinum resistance. Our group previously demonstrated a significant correlation between tissue Pt concentration and tumor response to Pt-based neoadjuvant chemotherapy (NAC) in lung cancer. We hypothesized that increased Pt concentration in radical cystectomy (RC) specimens would correlate with improved pathologic response to Pt-based NAC in MIBC. Methods A cohort of 19 clinically annotated, archived, fresh frozen RC specimens from patients with MIBC treated with Pt-based NAC was identified [ypT0 (pathologic complete response, pCR), N = 4; <= ypT1N0M0 (pathologic partial response, pPR), N = 6; >= ypT2 (minimal pathologic response/progression), N = 9)]. RC specimens from 2 patients with MIBC who did not receive NAC and 1 treated with a non-Pt containing NAC regimen were used as negative controls. Total Pt concentration in normal adjacent urothelial tissue and bladder tumors from RC specimens was measured by flameless atomic absorption spectrophotometry. Results Total Pt concentration in normal urothelium differed by tumor pathologic response (P = 0.011). Specimens with pCR had the highest Pt concentrations compared to those with pPR (P = 0.0095) or no response/progression (P = 0.020). There was no significant difference in Pt levels in normal urothelium and tumor between pPR and no response/progression groups (P = 0.37; P = 0.25, respectively). Conclusions: Our finding of increased intracellular Pt in RC specimens with pCR following NAC for MIBC compared to those with residual disease suggests that enhanced Pt accumulation may be an important determinant of Pt sensitivity. Factors that modulate intracellular Pt concentration, such as expression of Pt transporters, warrant further investigation as predictive biomarkers of response to Pt-based NAC in MIBC.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] The impact of smoking on pathologic response to neoadjuvant cisplatin-based chemotherapy in patients with muscle-invasive bladder cancer
    Philip H. Kim
    Matthew Kent
    Philip Zhao
    John P. Sfakianos
    Dean F. Bajorin
    Bernard H. Bochner
    Guido Dalbagni
    [J]. World Journal of Urology, 2014, 32 : 453 - 459
  • [2] The impact of smoking on pathologic response to neoadjuvant cisplatin-based chemotherapy in patients with muscle-invasive bladder cancer
    Kim, Philip H.
    Kent, Matthew
    Zhao, Philip
    Sfakianos, John P.
    Bajorin, Dean F.
    Bochner, Bernard H.
    Dalbagni, Guido
    [J]. WORLD JOURNAL OF UROLOGY, 2014, 32 (02) : 453 - 459
  • [3] Plasticity in muscle-invasive bladder cancer before and after cisplatin-based neoadjuvant chemotherapy
    Seiler, Roland
    Gibb, Ewan A.
    Takhar, Mandeep
    Van Kessel, Kim
    van Rhijn, Bas W. G.
    Winters, Brian
    Douglas, James
    Wang, Qiqi
    Choeurng, Voleak
    Erho, Nicholas
    Buerki, Christine
    Davicioni, Elai
    Sjodahl, Gottfrid
    Thalmann, George N.
    Zwarthoff, Ellen C.
    Boormans, Joost L.
    Dall'Era, Marc
    van der Heijden, Michiel S.
    Wright, Jonathan
    Black, Peter C.
    [J]. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2017, 35 (10) : 618 - 618
  • [4] Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer
    Plimack, Elizabeth R.
    Dunbrack, Roland L.
    Brennan, Timothy A.
    Andrake, Mark D.
    Zhou, Yan
    Serebriiskii, Ilya G.
    Slifker, Michael
    Alpaugh, Katherine
    Dulaimi, Essel
    Palma, Norma
    Hoffman-Censits, Jean
    Bilusic, Marijo
    Wong, Yu-Ning
    Kutikov, Alexander
    Viterbo, Rosalia
    Greenberg, Richard E.
    Chen, David Y. T.
    Lallas, Costas D.
    Trabulsi, Edouard J.
    Yelensky, Roman
    McConkey, David J.
    Miller, Vincent A.
    Golemis, Erica A.
    Ross, Eric A.
    [J]. EUROPEAN UROLOGY, 2015, 68 (06) : 959 - 967
  • [5] Feasibility of Cisplatin-Based Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer Patients With Diminished Renal Function
    Koshkin, Vadim S.
    Barata, Pedro C.
    Rybicki, Lisa A.
    Zahoor, Haris
    Almassi, Nima
    Redden, Alicia M.
    Fergany, Amr F.
    Kaouk, Jihad
    Haber, Georges-Pascal
    Stephenson, Andrew J.
    Ornstein, Moshe C.
    Gilligan, Timothy
    Garcia, Jorge A.
    Rini, Brian, I
    Grivas, Petros
    [J]. CLINICAL GENITOURINARY CANCER, 2018, 16 (04) : E879 - E892
  • [6] IDENTIFICATION OF MOLECULAR BIOMARKERS OF CISPLATIN-BASED CHEMOSENSITIVITY IN PATIENTS UNDERGOING NEOADJUVANT CHEMOTHERAPY FOR MUSCLE-INVASIVE BLADDER CANCER
    Shah, Paras
    Kozel, Zachary
    Lee, Annette
    Korsunsky, Ilya
    Shih, Andrew
    Yaskiv, Oksana
    Vira, Manish
    Bradley, Thomas
    Zhu, Xinhua
    [J]. JOURNAL OF UROLOGY, 2017, 197 (04): : E1196 - E1197
  • [7] Neoadjuvant cisplatin-based chemotherapy in "primary" and "secondary" muscle-invasive bladder cancer-is it a surrogate for molecular subtypes?
    Szarvas, Tibor
    Olah, Csilla
    Reis, Henning
    [J]. TRANSLATIONAL CANCER RESEARCH, 2019, 8 : S176 - S179
  • [8] Pathological TO Following Cisplatin-Based Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: A Network Meta-analysis
    Kim, Hyung Suk
    Jeong, Chang Wook
    Kwak, Cheol
    Kim, Hyeon Hoe
    Ku, Ja Hyeon
    [J]. CLINICAL CANCER RESEARCH, 2016, 22 (05) : 1086 - 1094
  • [9] Efficacy of Split Schedule Versus Conventional Schedule Neoadjuvant Cisplatin-Based Chemotherapy for Muscle-Invasive Bladder Cancer
    Osterman, Chelsea K.
    Babu, Dilip S.
    Geynisman, Daniel M.
    Lewis, Bianca
    Somer, Robert A.
    Balar, Arjun V.
    Zibelman, Matthew R.
    Guancial, Elizabeth A.
    Antinori, Gianna
    Yu, Shun
    Narayan, Vivek
    Guzzo, Thomas J.
    Plimack, Elizabeth R.
    Vaughn, David J.
    Fung, Chunkit
    Mamtani, Ronac
    [J]. ONCOLOGIST, 2019, 24 (05): : 688 - 690
  • [10] Immune-related biomarkers associated with pathologic complete response (pCR) to neoadjuvant cisplatin-based chemotherapy in patients with muscle-invasive bladder cancer undergoing cystectomy
    Ascierto, Maria L.
    Mendoza-Valderrey, Alberto
    Choe, Jane
    Kessler, Daria M.
    Li, Xinmin
    Linehan, Jennifer A.
    Twardowski, Przemyslaw W.
    [J]. CANCER RESEARCH, 2023, 83 (07)